Q3 2024 LeMaitre Vascular Inc Earnings Call Transcript
Key Points
- LeMaitre Vascular Inc (LMAT) reported a strong 16% sales growth in Q3 2024, driven by significant increases in grafts, patches, and carotid shunts.
- The company achieved a 49% EPS growth, showcasing robust profitability.
- APAC region led the growth with a 24% increase, particularly in Thailand and Korea, which are new direct markets.
- Gross margin improved to 67.8%, up 280 basis points year-over-year, driven by higher ASPs and direct labor efficiencies.
- LeMaitre Vascular Inc (LMAT) is expanding its sales force, aiming to reach 155 to 160 sales reps by year-end, indicating a strong focus on market penetration.
- Operating expenses increased by 11% in Q3 2024 compared to the previous year, which could impact future profitability if not managed.
- The company is still awaiting approval for seven MDR CE marks, which could delay market expansion in certain regions.
- There is uncertainty regarding the final submission and approval timeline for the XenoSure cardiac indication in China.
- The transition of CFO Joseph Pellegrino, who will retire in March 2025, may lead to temporary disruptions in financial leadership.
- Challenges in regulatory processes in Ireland and Germany for allograft approvals could delay product availability in these markets.
Welcome to the LeMaitre Vascular Q3 2024 financial results conference call. As a reminder, today's call is being recorded.
At this time, I would like to turn the call over to Mr. JJ Pellegrino, Chief Financial Officer of LeMaitre Vascular. Please go ahead, sir.
Thank you, operator. Good afternoon, and thank you for joining us on our Q3 2024 conference call. With me on today's call is our CEO, George LeMaitre; and our President, Dave Roberts.
Before we begin, I'll read our Safe Harbor statement. Today, we will make some forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast and similar expressions.
Our forward-looking statements are based on our estimates and assumptions as of today, October 31, 2024, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
